Format

Send to

Choose Destination
J Clin Gastroenterol. 2014 Nov-Dec;48 Suppl 1:S34-6. doi: 10.1097/MCG.0000000000000233.

Preliminary results on clinical effects of probiotic Lactobacillus salivarius LS01 in children affected by atopic dermatitis.

Author information

1
*Hospital of Foligno and Spoleto, AUSL 2 Umbria ‡IRCCS Galeazzi Hospital Milan †Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.

Abstract

GOALS:

The goal of this study was to evaluate the clinical efficacy of an intake of Lactobacillus salivarius LS01 (DSM 22775) for the treatment of atopic dermatitis (AD) in children.

BACKGROUND:

AD is an inflammatory and pruritic chronic relapsing skin disorder with multifactorial etiopathology. Some evidence suggests that probiotics may improve AD by modulating the immune system and the composition of intestinal microbiota.

STUDY:

A total of 43 patients aged from 0 to 11 years were enrolled in the study (M/F ratio=1:1) and treated with the probiotic strain L. salivarius LS01. Clinical efficacy of probiotic treatment was assessed from baseline by changes in itch index and in the objective SCORAD/SCORAD index.

RESULTS:

Patients being given probiotic treatment showed a significant improvement in clinical parameters (SCORAD and itch values) from baseline. The reduction in SCORAD and itch index observed after 4 weeks of treatment also persisted after the cessation of probiotic supplementation.

CONCLUSIONS:

L. salivarius LS01 seems to be able to improve the quality of life of children affected by AD and, as a consequence, it may have promising clinical and research implications.

PMID:
25291124
DOI:
10.1097/MCG.0000000000000233
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center